Document Detail


Impact of host and virus genome variability on HCV replication and response to interferon.
MedLine Citation:
PMID:  23835049     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Since the discovery of hepatitis C virus (HCV), treatment has proven difficult and the regimen of pegylated interferon-α and ribavirin is only effective for half of patients. Evidence suggests that host and viral genome variations play a role in either viral clearance or persistence. Powerful genomic technologies have made it possible to study genome-wide associations with treatment response, which yielded critical genetic polymorphisms that predict treatment response. This has important implications for treatment of HCV infection and opened the door to the possibility of genetic marker-guided treatment (personalized medicine). This review will focus on the recent advances in understanding host and viral genetic variations with regards to treatment and the importance for future therapeutic intervention.
Authors:
Cameron J Schweitzer; T Jake Liang
Related Documents :
2735469 - Hiv testing in prisoners: is mandatory testing mandatory?
11366659 - Washington upholds hiv exposure law as constitutional.
24040359 - Sexual behavior and condom use among seasonal dalit migrant laborers to india from far ...
24012819 - Therapy of chronic hepatitis c virus infection in the era of direct-acting and host-tar...
11366619 - Michigan man sentenced for not disclosing hiv status.
24659359 - Using the national hiv behavioral surveillance system to inform hiv prevention efforts ...
22834489 - Ctgc motifs within the hiv core promoter specify tat-responsive pre-initiation complexes.
17604129 - A replicon-based shuttle vector system for assessing the phenotype of hcv ns5b polymera...
20841439 - Lopinavir/ritonavir dosage form affects quality of life during monotherapy in hiv-posit...
Publication Detail:
Type:  Journal Article; Review     Date:  2013-07-06
Journal Detail:
Title:  Current opinion in virology     Volume:  3     ISSN:  1879-6265     ISO Abbreviation:  Curr Opin Virol     Publication Date:  2013 Oct 
Date Detail:
Created Date:  2013-10-14     Completed Date:  2014-04-30     Revised Date:  2014-10-09    
Medline Journal Info:
Nlm Unique ID:  101560941     Medline TA:  Curr Opin Virol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  501-7     Citation Subset:  IM    
Copyright Information:
Published by Elsevier B.V.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antiviral Agents / therapeutic use*
Genetic Variation / drug effects
Genome, Viral / drug effects*
Hepacivirus / drug effects*,  genetics,  physiology
Hepatitis C / drug therapy*,  genetics*,  virology
Humans
Interferon-alpha / therapeutic use
Treatment Outcome
Virus Replication / drug effects*
Grant Support
ID/Acronym/Agency:
Z99 DK999999/DK/NIDDK NIH HHS; ZIA DK054504-15/DK/NIDDK NIH HHS; ZIA DK054504-16/DK/NIDDK NIH HHS; ZIA DK054505-15/DK/NIDDK NIH HHS; ZIA DK054505-16/DK/NIDDK NIH HHS; ZIA DK054511-05/DK/NIDDK NIH HHS; ZIA DK054511-06/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  To dream the impossible dream: universal influenza vaccination.
Next Document:  Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity: a case-control ...